Want to see IN:NATCOPHARM full AI Analyst Report?
NATCO Pharma Limited (NATCOPHARM) Stock Forecast & Price Target
NATCOPHARM Analyst Ratings
There are no analyst ratings in the last 3 months.
NATCOPHARM Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Analyst Profile | Expert Firm | Price Target | Position | Upside / Downside | Action | Date | Follow | Article |
|---|---|---|---|---|---|---|---|---|
| PerPlexity - SonarReasoningPro | TipRanks - PerPlexity | INR 933→INR 920 | buy | 17.57%Upside | Reiterated | 10/02/26 | ||
| Google General IN | TipRanks - Google | INR 933→INR 920 | buy | 17.57%Upside | Reiterated | 10/02/26 | ||
| Anthropic General IN | TipRanks - Anthropic | INR 899→INR 904 | buy | 15.53%Upside | Upgraded | 10/02/26 | ||
| OpenAI - Gpt-5.6Sol | TipRanks - OpenAI | INR 928→INR 916 | buy | 17.06%Upside | Reiterated | 10/02/26 | ||
| DeepSeek - V4Pro | TipRanks - DeepSeek | INR 916→INR 912 | buy | 16.55%Upside | Reiterated | 10/02/26 | ||
| xAI - Grok-4.3 | TipRanks - xAI | INR 933→INR 929 | buy | 18.72%Upside | Reiterated | 10/02/26 |
| Analyst Profile | Date | Price Target | Position | Upside / Downside | Action | Follow | Article | Expert Firm |
|---|---|---|---|---|---|---|---|---|
| PerPlexity - SonarReasoningPro | 10/02/26 | INR 933→INR 920 | buy | 17.57%Upside | Reiterated | TipRanks - PerPlexity | ||
| Google General IN | 10/02/26 | INR 933→INR 920 | buy | 17.57%Upside | Reiterated | TipRanks - Google | ||
| Anthropic General IN | 10/02/26 | INR 899→INR 904 | buy | 15.53%Upside | Upgraded | TipRanks - Anthropic | ||
| OpenAI - Gpt-5.6Sol | 10/02/26 | INR 928→INR 916 | buy | 17.06%Upside | Reiterated | TipRanks - OpenAI | ||
| DeepSeek - V4Pro | 10/02/26 | INR 916→INR 912 | buy | 16.55%Upside | Reiterated | TipRanks - DeepSeek | ||
| xAI - Grok-4.3 | 10/02/26 | INR 933→INR 929 | buy | 18.72%Upside | Reiterated | TipRanks - xAI |
Best Analysts Covering NATCO Pharma Limited
Copying Anthropic General IN's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -3.50% per trade.
Copying Anthropic General IN's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -3.50% per trade.
Copying Anthropic General IN's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -3.50% per trade.
NATCOPHARM Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 0 | 0 | 0 | 0 | 0 |
In the current month, NATCOPHARM has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NATCOPHARM average Analyst price target in the past 3 months is ―.
NATCOPHARM Financial Forecast
NATCOPHARM Earnings Forecast
Next quarter’s earnings estimate for NATCOPHARM is INR 9.07 with a range of INR 6.80 to INR 10.32. The previous quarter’s EPS was INR 11.41. NATCOPHARM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year NATCOPHARM has Performed in-line its overall industry.
NATCOPHARM Sales Forecast
Next quarter’s sales forecast for NATCOPHARM is INR 7.79B with a range of INR 7.11B to INR 9.19B. The previous quarter’s sales results were INR 7.35B. NATCOPHARM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year NATCOPHARM has Performed in-line its overall industry.